#1
|
|||
|
|||
Âûáîð ïðåïàðàòà ïðè ïîñòòðàâìàòè÷åñêîé ýïèëåïñèè è á-íè Øàðêî-Ìàðè-Òóñà
Âûáîð ïðîòèâîñóäîðîæíîãî ïðåïàðàòà ïðè ïîñòòðàâìàòè÷åñêîé ýïèëåïñèè ó áîëüíîãî ñ áîëåçíüþ Øàðêî--Ìàðè--Òóñà.
Âîïðîñ ê óâàæàåìûì íåâðîëîãàì. Ìóæ÷èíà, 55 ëåò.  20 ëåò -- ×ÌÒ, ðàííÿÿ ïîñòòðàâìàòè÷åñêàÿ ýïèëåïñèÿ. Ïîñëå ïðîìåæóòêà îêîëî 10 ëåò ïîÿâèëèñü áåçñóäîðîæíûå ïðèïàäêè (âíåçàïíûå ïîòåðè ñîçíàíèÿ), ïîñëåäíèå íåñêîëüêî ëåò ïîÿâèëèñü ãåíåðàëèçîâàííûå ñóäîðîæíûå ïðèïàäêè. Ñåé÷àñ ïðèïàäêè âîçíèêàþò îò îäíîãî äî íåñêîëüêèõ ðàç â ìåñÿö, ïðîâîöèðóþòñÿ ñòðåññàìè, àëêîãîëåì. Êðîìå òîãî, ñòðàäàåò áîëåçíüþ Øàðêî--Ìàðè--Òóñà (ñíèæåíèå ÷óâñòâèòåëüíîñòè, àòðîôèÿ ìûøö ïðåèìóùåñòâåííî íèæíèõ êîíå÷íîñòåé, õîäèò ñàìîñòîÿòåëüíî, íî ñ ïàëêîé). Ïðîòèâîñóäîðîæíîé òåðàïèè íèêàêîé íå ïîëó÷àë. Êàêîâ îïòèìàëüíûé âûáîð ïðîòèâîñóäîðîæíîãî ïðåïàðàòà? Íåîáõîäèìî ëè ó÷èòûâàòü ïðè âûáîðå ïðåïàðàòà íåðâíî-ìûøå÷íîå çàáîëåâàíèå? |
#2
|
||||
|
||||
Óâàæàåìûé Àðòåìèé! Íåâðàëüíàÿ àìèîòðîôèÿ Ø-Ì-Ò - íàñëåäñòâåíîå ìåäëåííî ïðîãðåññèðóþùåå çàáîëåâàíèå, ñïåöèôè÷åñêîãî ëå÷åíèÿ íå èìååò.
 îòíîøåíèè ñàìèõ ýïèïðèïàäêîâ âñå ñëîæíåå: ñëèøêîì îòñðî÷åííûå ïîñëå òðàâìû, íå î÷åíü ïîíÿòíî ïðîãðåññèðóþùåå òå÷åíèå. Ïðîâîäèëîñü ëè ëå÷åíèå áåññóäîðîæíûõ ïðèïàäêîâ? Åñòü ëè àóðà?  ëþáîì ñëó÷àå, â ïîðÿäêå ýêñòðåííîé ïîìîùè íàçíà÷üòå, íàïðèìåð (ïî ïðèíöèïó äîñòóïíîñòè è óíèâåðñàëüíîñòè), êàðáàìàçåïèí 200 ìã 3 ðàçà â äåíü è, ïî âîçìîæíîñòè, äîîáñëåäóéòå ïàöèåíòà: ÌÐÒ, ÝÝÃ. Àëêîãîëü, ïîíÿòíî, íàäî èñêëþ÷èòü.  äàëüíåéøåì ìîæåò ïîíàäîáèòüñÿ êîððåêöèÿ äîçû êàðáàìàçåïèíà ïî ýôôåêòó è êîíöåíòðàöèè â êðîâè. Àíòèêîíâóëüñàíòû íå äîëæíû óõóäøèòü òå÷åíèå ØÌÒ, èõ íàçíà÷åíèå íåîáõîäèìî. |
#3
|
||||
|
||||
Óâàæàåìûé Àðòåìèé! Ïîçâîëüòå âëåçòü ñî ñâîèì ìíåíèåì. Ñîõðàíÿþòñÿ ëè áåññóäîðîæíûå ïðèïàäêè? Â êàêîå âðåìÿ ñóòîê ïðåèìóùåñòâåííî âîçíèêàþò ïðèïàäêè? ×òî íà ÝÝÃ?
ß áû âñ¸-òàêè íà÷àëà ñ âàëüïðîàòîâ -ó íèõ øèðå ñïåêòð äåéñòâèÿ íà ðàçëè÷íûå ïðèïàäêè è ëó÷øå ïåðåíîñèìîñòü. È åù¸ âàæíî - ëó÷øå íàçíà÷àòü ïðîëîíãèðîâàííûå ôîðìû - èõ ïðîùå ïðèíèìàòü (2ðàçà, à íå 3 â ñóòêè, ìåíüøå âåðîÿòíîñòü ïðîïóñòèòü î÷åðåäíîé ïðè¸ì) è ìåíüøå êîëåáàíèÿ êîíöåíòðàöèè â êðîâè (íà ðåäóêöèþ êîíöåíòðàöèè òîæå ìîãóò áûòü ïðèïàäêè). Íàïðèìåð, äåïàêèí-õðîíî, äîçà ðàñ÷èòûâàåòñÿ ïî ìàññå òåëà. Ëþáîé àíòèêîíâóëüñàíò ëó÷øå ââîäèòü ïîñòåïåííî. Íàïèøèòå âåñ ÷åëîâåêà è âðåìÿ ñóòîê ïðåèìóùåñòâåííîãî âîçíèêíîâåíèÿ ïðèïàäêîâ, îáñ÷èòàåì äîçó è ñõåìó ïðè¸ìà. Ïîëíîñòüþ ñîãëàñíà ñ Ýðèêîì, ÷òî îáñëåäîâàòü ïàöèåíòà íóæíî. Îòðèöàòåëüíàÿ äèíàìèêà ìîæåò áûòü ñâÿçàíà ñ ïðè¸ìîì àëêîãîëÿ, íî ýòî âñ¸ æå òðåâîæíûé çâîíî÷åê. ÌÐÒ -îáÿçàòåëüíî. Àëêîãîëü - èñêëþ÷èòü ðàäèêàëüíî! Âîò åù¸ âàæíî: åñòü ëè ôîêàëüíûé êîìïàíåíò, ò.å., íà÷àëî ïðèïàäêà ñ êðèêà èëè ïîâîðîòà ãîëîâû â îïðåäåë¸ííóþ ñòîðîíó èëè ñóäîðîã â îïðåäåë¸ííîé/íûõ êîíå÷íîñòè (Äæåêñîíîâñêèé ìàðø) äî ïîòåðè ñîçíàíèÿ è ïîòîì ãåíåðàëèçàöèÿ. Ýòî ìîæíî âûÿñíèòü òîëüêî ñî ñëîâ î÷åâèäöåâ. |
#4
|
||||
|
||||
Ïðî âàëüïðîàòû ñîãëàñåí, òîëüêî öåíà ïî÷òè â 20 ðàç âûøå. Íàäåþñü ïàöèåíò - ëüãîòíèê.
|
#5
|
||||
|
||||
Öèòàòà:
Âîò, íàïðèìåð, öåíû íà äåïàêèí [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] À îòå÷åñòâåííûé êàðáàìàçåïèí ïî ýôôåêòèâíîñòè ñðàâíèì ñ ïëàöåáî , ê ñîæàëåíèþ, ò.å. ñðàâíèâàòü öåíû íóæíî ñ ôèíëåïñèíîì ðåòàðä èëè òåãðåòîëîì ( åñëè ëå÷èòüñÿ). Íî è ôèíëåïñèí, êñòàòè, â ñïèñêàõ äîëæåí áûòü. |
#6
|
|||
|
|||
Ñïàñèáî çà áûñòðûé îòêëèê. Ïîêà íàçíà÷èë êàðáàìàçåïèí (èç ñîîáðàæåíèé äåøåâèçíû è äîñòóïíîñòè). Ïîäðîáíåå íàïèøó ïîçæå.
|
#7
|
|||
|
|||
Äåïàêèí èç ñïèñêà ïðîïàë. Åñòü êîíâóëåêñ.
|
#8
|
|||
|
|||
Âåðîÿòíåå âñåãî ó áîëüíîãî âèñî÷íàÿ ýïèëåïñèÿ - ñðåäñòâî âûáîðà êàðáàìàçåïèí.
 ëþáîì ñëó÷àå - ýïèëåïñèÿ ïàðöèàëüíàÿ. Ýôôåêòèâíîñòü âûëüïðîàòîâ ïðè ïàðöèàëüíûõ ýïèëåïñèÿõ íèæå, ÷åì ýôôåêòèâíîñòü êàðáàìàçåïèíà. Ìîé ñîâåò,åñëè åñòü âîçìîæíîñòü ïîòðàòèòü 600-700 ðóá â ìåñÿö íàçíà÷àéòå - òåãðåòîë ÖÐ èëè ôèíëåïñèí-ðåòàðä. (Ô-ðåòàðä - áûëè æàëîáû íà ïîääåëêè). Êàðáàìàçåïèí ðîññèéñêèé -ñòîèò òî ëè 7 òîëè 17 ðóáëåé. Íå çíàþ èç ÷åãî åãî äåëàþò. Ðàíüøå áûëè åù¸ íå òàêèå äîðîãèå êàðáàìàçåïèí-íèêîìåä è àïî-êàðáàìàçåïèí. Íå ïîìíþ, ÷òîáû íàçíà÷àëà, íî ôèðìû óâàæàåìûå. Âûáèðàéòå. Ñ íàèëó÷øèìè ïîæåëàíèÿìè, Àìèíà |
#9
|
|||
|
|||
Öèòàòà:
íå çàìåòèëà íèêàêîé ðàçíèöû ìåæäó íàèáîëåå ðàñïðîñòðàí¸ííìè ôîðìàìè âàëüïðîàòîâ. à ñòîèìîñòü êîíâóëåêñà â 4 ðàçà äåøåâëå, ÷åì ó äåïàêèíà-õðîíî. À òî ÷òî äåïàêèí ïðîïàë èç ñïèñêà - ïðåñòóïëåíèå. Èç ñïèñêà óäàëèëè âñå îðèãèíàëüíûå ÀÝÏ, åñëè èìåþòñÿ èõ ìåíåå äîðîãèå æåíåðèêè. |
#10
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#11
|
||||
|
||||
New research suggests lamotrigine should replace carbamazepine as first-line therapy for patients with partial epilepsy, and valproate should be the first drug of choice for generalized and unclassifiable epilepsy. These are the conclusions of the Standard and New Antiepileptic Drugs (SANAD) trial, which includes results from 2 concurrent unblinded randomized studies from in hospital-based outpatient clinics in the United Kingdom. The studies and an accompanying comment appear in the March 24 issue of The Lancet.
Pearls for Practice The current drug of choice for patients with newly diagnosed generalized and unclassifiable seizures is valproate, whereas carbamazepine is the widely accepted choice for partial onset seizures. Lamotrigine is clinically better than carbamazepine for time-to-treatment failure outcomes and is therefore an alternative for patients diagnosed with partial onset seizures. Valproate is better tolerated than topiramate and more efficacious than lamotrigine and should remain the drug of first choice for many patients with generalized and unclassifiable epilepsies. ïîäðîáíåå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |